ASR Vermogensbeheer N.V. Has $3.30 Million Stock Position in ResMed Inc. $RMD

ASR Vermogensbeheer N.V. raised its holdings in ResMed Inc. (NYSE:RMD) by 4.4% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 12,796 shares of the medical equipment provider’s stock after acquiring an additional 542 shares during the period. ASR Vermogensbeheer N.V.’s holdings in ResMed were worth $3,301,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. ICW Investment Advisors LLC increased its position in ResMed by 0.4% during the first quarter. ICW Investment Advisors LLC now owns 11,394 shares of the medical equipment provider’s stock worth $2,551,000 after acquiring an additional 41 shares during the period. Smartleaf Asset Management LLC grew its position in ResMed by 3.9% in the 1st quarter. Smartleaf Asset Management LLC now owns 1,222 shares of the medical equipment provider’s stock worth $269,000 after purchasing an additional 46 shares during the last quarter. E Fund Management Co. Ltd. grew its position in ResMed by 2.8% in the 1st quarter. E Fund Management Co. Ltd. now owns 1,719 shares of the medical equipment provider’s stock worth $385,000 after purchasing an additional 47 shares during the last quarter. CVA Family Office LLC grew its position in ResMed by 29.8% in the 1st quarter. CVA Family Office LLC now owns 209 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 48 shares during the last quarter. Finally, V Square Quantitative Management LLC grew its position in ResMed by 3.0% in the 2nd quarter. V Square Quantitative Management LLC now owns 1,747 shares of the medical equipment provider’s stock worth $451,000 after purchasing an additional 51 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

Insiders Place Their Bets

In related news, General Counsel Michael J. Rider sold 100 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $274.36, for a total transaction of $27,436.00. Following the transaction, the general counsel owned 11,327 shares in the company, valued at $3,107,675.72. This represents a 0.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Hernandez sold 2,575 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $287.10, for a total transaction of $739,282.50. Following the transaction, the director owned 4,045 shares in the company, valued at $1,161,319.50. The trade was a 38.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,743 shares of company stock valued at $5,075,239. 0.71% of the stock is currently owned by corporate insiders.

ResMed Price Performance

NYSE:RMD opened at $278.48 on Friday. The firm has a market cap of $40.77 billion, a PE ratio of 29.28, a price-to-earnings-growth ratio of 1.86 and a beta of 0.83. ResMed Inc. has a 12 month low of $199.92 and a 12 month high of $293.81. The company has a quick ratio of 2.53, a current ratio of 3.44 and a debt-to-equity ratio of 0.11. The company’s 50-day moving average price is $278.16 and its two-hundred day moving average price is $253.46.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, July 31st. The medical equipment provider reported $2.55 EPS for the quarter, topping the consensus estimate of $2.47 by $0.08. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.33 billion. ResMed had a return on equity of 25.62% and a net margin of 27.22%.ResMed’s revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.08 EPS. On average, equities analysts anticipate that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 18th. Shareholders of record on Thursday, August 14th were paid a $0.60 dividend. This is an increase from ResMed’s previous quarterly dividend of $0.53. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 14th. ResMed’s payout ratio is presently 25.24%.

Analyst Upgrades and Downgrades

RMD has been the topic of several research reports. Royal Bank Of Canada boosted their price target on ResMed from $294.00 to $300.00 and gave the company an “outperform” rating in a research note on Friday, August 1st. Citigroup assumed coverage on ResMed in a report on Thursday, September 18th. They set a “buy” rating and a $330.00 price objective on the stock. Weiss Ratings reiterated a “buy (b-)” rating on shares of ResMed in a research note on Saturday, September 27th. Wall Street Zen downgraded shares of ResMed from a “buy” rating to a “hold” rating in a research note on Sunday, August 10th. Finally, Mizuho lifted their target price on shares of ResMed from $270.00 to $290.00 and gave the company an “outperform” rating in a research report on Friday, August 1st. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, ResMed presently has an average rating of “Moderate Buy” and a consensus target price of $294.20.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.